Hepathromb

Hepathromb is a pharmaceutical product that contains the active ingredient heparin sodium. It is supplied in an unspecified dosage form and strength, and is marketed within the European Union. As an anticoagulant belonging to the antithrombotic therapeutic class, Hepathromb works by enhancing the activity of antithrombin III to inhibit clotting factors. The product is intended for use under medical supervision and appropriate clinical monitoring by qualified healthcare professionals.

Hepathromb is used in clinical settings where anticoagulation is required to prevent or treat thrombotic events.

- Prevention of venous thromboembolism in patients undergoing surgery or immobilization. - Management of acute coronary syndromes where clot formation is a risk. - Adjunct therapy during hemodialysis to maintain circuit patency. - Treatment of established deep vein thrombosis or pulmonary embolism under supervision. - Prophylaxis of clot formation in patients with atrial fibrillation undergoing certain procedures. - Support of anticoagulation during cardiopulmonary bypass when rapid reversal may be needed.

Side effects associated with heparin sodium, the active component of Hepathromb, vary in frequency and severity.

Common: - Minor bruising or bleeding at injection sites. - Small hematomas. - Mild thrombocytopenia (platelet count reduction). - Nausea or mild headache.

Serious: - Major hemorrhage (internal or external). - Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis. - Allergic reactions such as urticaria or anaphylaxis. - Elevated liver enzymes indicating hepatic involvement.

When prescribing or administering Hepathromb, healthcare professionals should consider several precautionary measures to ensure patient safety.

- Assess baseline coagulation parameters and platelet count before initiation. - Review patient history for bleeding disorders, recent surgery, or trauma. - Monitor for signs of bleeding during therapy, especially in the gastrointestinal and intracranial regions. - Adjust dose or discontinue if significant thrombocytopenia develops. - Use caution in patients with renal or hepatic impairment, as drug clearance may be altered. - Avoid use in pregnancy unless benefits outweigh risks, after specialist consultation.

Heparin sodium can interact with other medications, affecting its anticoagulant effect or increasing bleeding risk.

Avoid: - Concurrent use of other anticoagulants such as warfarin, direct oral anticoagulants, or low‑molecular‑weight heparins. - Antiplatelet agents like clopidogrel or aspirin when combined may amplify bleeding. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that impair platelet function.

Use with caution: - Certain antibiotics (e.g., vancomycin) that may potentiate anticoagulation. - Thrombolytic agents used in acute clot dissolution. - High‑dose corticosteroids that can affect platelet stability.